Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.
Frontiers JournalsOct 22 2024 Antibody -drug conjugates have emerged as a promising approach in cancer therapy , offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.
The mechanism of action of bispecific ADCs involves binding to multiple antigens, facilitating receptor clustering and internalization, and releasing cytotoxic payloads within tumor cells, leading to apoptosis. This dual-targeting strategy can also induce a bystander effect, where the released payload affects neighboring tumor cells.
Anti-HER2 bispecific ADCs like ZW49 and MEDI4276 are in clinical trials, showing potential in treating HER2-expressing cancers. M1231, which targets MUC1 and EGFR, has also shown promising results in preclinical models and is in phase I clinical trials for solid tumors.
Cancer Therapy Antibodies Antibody Conjugation Drugs Efficacy Evolution Preclinical Research Technology Tumor
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Advancements in AI-driven sensors transform pain managementA review paper by scientists at the Indiana University Bloomington summarized recent engineering efforts in developing various sensors and devices for addressing challenges in the personalized treatment of pain.
Read more »
Long-lived plasma cells fail to establish after COVID mRNA vaccination, limiting long-term antibody responseResearchers found that SARS-CoV-2-specific plasma cells were largely excluded from the long-lived plasma cell compartment in the bone marrow after mRNA vaccination, explaining the short-lived antibody response.
Read more »
Campylobacter jejuni-specific antibody gives hope to vaccine developmentBacterial infections resulting in enteritis, and sometimes extra-intestinal infections such as sepsis, continue to be a global health concern.
Read more »
New antibody targets cancer-causing HER2 mutationsFor some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing cancer.
Read more »
De novo antibody protein sequencing reveals novel functional and neutralizing antibodies Post-SARS-CoV-2 vaccinationRapid Novor has published a study that highlights the power of combining de novo antibody protein sequencing with conventional proteomics to uncover functional and neutralizing antibodies in human plasma following SARS-CoV-2 vaccination.
Read more »
The rapid characterization of a monoclonal antibodyDiscover the different modes of stirring stress during bioprocessing on a monoclonal antibody.
Read more »